Summary
Spontaneous and drug-induced liberation of 14C-5-hydroxytryptamine (14C-5HT), 3H-dopamine (3H-DA) and 3H-noradrenaline (3H-NA) from normal and reserpinized human blood-platelets has been determined from measurements of the amine contents before and after incubation in tris-buffer. In normal platelets the spontaneous liberation of 3H-catecholamines was more marked than that of 14C-5HT, but was less in percent for all these labelled amines than in reserpinized platelets. Thrombin lowered amine contents more in normal than in reserpinized platelets. The initial thrombin-induced decrease of 14C-5HT, in contrast to that of 3H-catecholamines, showed a partial recovery after 30 min which was abolished by imipramine. The benzoquinolizine Ro 4-1284 diminished all the amines in normal, but not in reserpinized platelets. In normal platelets tyramine affected 14C-5HT and 3H-DA about equally, whereas 3H-NA much less. Octopamine showed a similar pattern as tyramine, but was less potent. P-chlormethamphetamine (PCMA) and amphetamine decreased 3H-DA less markedly than 14C-5HT and 3H-NA not at all. In reserpinized platelets these arylalkylamines induced a decrease of 14C-5HT but not of 3H-catecholamines. It is concluded that (a) 3H-catecholamines like 14C-5HT are mainly localized in the granular pool of normal human platelets, (b) the pattern of action of a drug on intra- and extragranular amines depends not only on the nature of the drug and the amine to be liberated, but in comparison with previous results also on the species, (c) platelets are not completely satisfactory models for monoaminergic neurons, especially catecholaminergic ones regarding drug-induced amine liberation.
Similar content being viewed by others
References
Barbeau A, Campanella G, Butterworth RF, Yamada K (1975) Uptake and efflux of 14C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease. Neurology 25:1–9
Berneis KH, Pletscher A, Da Prada M (1970) Phase separation in solutions of noradrenaline and adenosine triphosphate: influence of bivalent cations and drugs. Br J Pharmacol 39:382–389
Boullin DJ, O'Brian RA (1970) Accumulation of dopamine by blood platelets from normal subjects and Parkinsonian patients under treatment with L-Dopa. Br J Pharmacol 39:779–788
Da Prada M, Picotti GB (1979) Content and subcellular localisation of catecholamines and 5-hydroxytryptamine in human and animal blood platelets: monoamine distribution between platelets and plasma. Br J Pharmacol 65:653–662
Da Prada M, Pletscher A (1969) Storage of exogenous monoamines and reserpine in 5-hydroxytryptamine organelles of blood platelets. Eur J Pharmacol 7:45–48
Fischer JE, Kopin IJ (1964) Evidence for intra- and extraneuronal reserpine-resistant norepinephrine (NE) pools. Fed Proc 23:I, 349
Glover V, Sandler M, Owen F, Riley GR (1977) Dopamine is a monoamine oxidase substrate B in man. Nature 265:80–81
Laubscher A, Pletscher A (1979) Shape change and uptake of 5-hydroxytryptamine in human blood platelets: action of neuropsychotropic drugs. Life Sci 24:1833–1840
Mattiasson I, Mattiasson B, Hood B (1979) The reflux rate of norepinephrine from platelets and its relation to blood pressure. Life Sci 24:2265–2272
Pletscher A (1978) Platelets as models for monoaminergic neurons. In: Youdim MBH (ed) Essays in neurochemistry and neuropharmacology, vol 3. John Wiley and Sons Ltd, London, pp 49–101
Pletscher A (1980) Liberation of catecholamines from blood platelets. Br J Pharmacol (in press for publication 1980)
Pletscher A, Brossi A, Gey KF (1962) Benzoquinolizine derivatives: a new class of monoamine-decreasing drugs with psychotropic action. In: Int Rev of Neurobiology, vol 4. Academic Press Inc, New York, pp 275–306
Pletscher A, Bartholini G, Bruderer H, Burkard WP, Gey KF (1964) Chlorinated arylalkylamines affecting the cerebral metabolism of 5-hydroxytryptamine. J Pharmacol Exp Ther 145:344–350
Pletscher A, Da Prada M, Burkard WP, Tranzer JP (1968) Effects of benzoquinolizines and ring substituted arylalkylamines on serotonin metabolism. In: Adv Pharmacol 6 B. Academic Press Inc, New York/London, pp 55–69
Pletscher A, Da Prada M, Berneis KH, Tranzer JP (1971) New aspects on the storage of 5-hydroxytryptamine in blood platelets. Experientia 27:993–1002
Pletscher A, Laubscher A, Graf M, Saner A (1979) Blood platelets as models for central 5-hydroxytryptaminergic neurons. Ann Biol Clin 37:35–39
Reimers HJ, Kinlough-Rathbone RL, Cazenave JP, Senyi AF, Hirsch J, Packham MA, Mustard JF (1976) In vitro and in vivo functions of thrombin-treated platelets. Thromb Haemostas 35:151–166
Ricaurte GA, Schuster CR, Seiden LS (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 193:153–163
Ross SB (1977) On the mode of action of central stimulatory agents. Acta Pharmacol Toxicol 41:392–396
Ross SB (1979) Interactions between reserpine and various compounds on the accumulation of 14C-5-hydroxytryptamine and 3H-noradrenaline in homogenates from rat hypothalamus. Biochem Pharmacol 28:1085–1088
Shore PA (1962) Release of serotonin and catecholamines by drugs. Pharmacol Rev 14:531–550
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peyer, M., Pletscher, A. Liberation of catecholamines and 5-hydroxytryptamine from human blood-platelets. Naunyn-Schmiedeberg's Arch. Pharmacol. 316, 81–86 (1981). https://doi.org/10.1007/BF00507232
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00507232